Voyager Therapeutics Financial Statements 2013-2025 | VYGR

Revenue

$80.001

$250.008

$40.907

$37.415

$171.128

$104.391

$7.619

$10.135

$14.22

$17.334

Cost Of Goods Sold

Gross Profit

$80.001

$250.008

$40.907

$37.415

$171.128

$104.391

$7.619

$10.135

$14.22

$17.334

Research And Development Expenses

$127.368

$92.172

$60.764

$73.787

$108.753

$119.735

$64.905

$62.26

$42.249

$27.679

SG&A Expenses

$35.92

$35.822

$30.98

$37.246

$34.991

$36.335

$33.809

$19.738

$13.27

$9.909

Other Operating Income Or Expenses

Operating Expenses

Operating Income

$-83.287

$122.014

$-50.837

$-73.618

$27.384

$-51.679

$-91.095

$-71.863

$-41.299

$-20.254

Total Non-Operating Income/Expense

$18.95

$11.724

$4.445

$2.421

$9.357

$8.082

$2.627

$1.165

$1.158

$-9.418

Pre-Tax Income

$-64.337

$133.738

$-46.392

$-71.197

$36.741

$-43.597

$-88.468

$-70.698

$-40.141

$-29.672

Income Taxes

$0.665

$1.408

$0.016

$-0.18

$0.052

Income After Taxes

$-65.002

$132.33

$-46.408

$-71.197

$36.741

$-43.597

$-88.288

$-70.698

$-40.193

$-29.672

Other Income

Income From Continuous Operations

$-65.002

$132.33

$-46.408

$-71.197

$36.741

$-43.597

$-88.288

$-70.698

$-40.193

$-29.672

Income From Discontinued Operations

Net Income

$-65.002

$132.33

$-46.408

$-71.197

$36.741

$-43.597

$-88.288

$-70.698

$-40.193

$-38.29

EBITDA

$-86.525

$122.829

$-44.662

$-68.104

$31.228

$-52.498

$-91.141

$-70.292

$-39.991

$-19.202

EBIT

$-83.287

$122.014

$-50.837

$-73.618

$27.384

$-51.679

$-91.095

$-71.863

$-41.299

$-20.254

Basic Shares Outstanding

Shares Outstanding

Basic EPS

$-1.13

$3.08

$-1.21

$-1.89

$0.99

$-1.21

$-2.75

$-2.64

$-1.59

$-9.14

EPS - Earnings Per Share

$-1.13

$2.97

$-1.21

$-1.89

$0.98

$-1.21

$-2.75

$-2.64

$-1.59

$-9.14